Get the Stockscreener App
155.04
2.79%
4.21
After Hours:
154.82
-0.22
-0.14%
Belite Bio Inc Adr stock is traded at $155.04, with a volume of 126.19K.
It is up +2.79% in the last 24 hours and down -17.55% over the past month.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
See More
Previous Close:
$150.83
Open:
$153
24h Volume:
126.19K
Relative Volume:
0.61
Market Cap:
$6.10B
Revenue:
-
Net Income/Loss:
$-77.61M
P/E Ratio:
-67.47
EPS:
-2.2979
Net Cash Flow:
-
1W Performance:
-3.90%
1M Performance:
-17.55%
6M Performance:
+121.45%
1Y Performance:
+140.37%
1-Day Range:
$153.00
$159.45
1-Week Range:
$146.61
$162.00
52-Week Range:
$49.00
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
155.04 | 5.93B | 0 | -77.61M | 0 | -2.2979 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-26 | Initiated | BofA Securities | Buy |
| Jan-06-26 | Initiated | Morgan Stanley | Overweight |
| Dec-02-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-24-25 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-20-25 | Initiated | Mizuho | Neutral |
| Dec-14-23 | Initiated | Maxim Group | Buy |
| Jul-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-23 | Initiated | SVB Securities | Outperform |
| Aug-01-22 | Initiated | H.C. Wainwright | Buy |
| Jul-01-22 | Initiated | The Benchmark Company | Buy |
View All
Belite Bio Inc Adr Stock (BLTE) Latest News
Belite Bio (NASDAQ:BLTE) Stock Rating Lowered by Wall Street Zen - MarketBeat
Belite Bio (NASDAQ: BLTE) CMO details option grants and indirect holdings - Stock Titan
Belite Bio (NASDAQ: BLTE) CSO details stock options and share stakes - Stock Titan
Belite Bio (BLTE) CFO Chuang Hao-Yuan details options and shares in Form 3 - Stock Titan
Belite Bio (NASDAQ: BLTE) director discloses 400 ADS position - Stock Titan
BELITE BIO (BLTE) director Longo reports 110,000-share stock option holdings - Stock Titan
Belite Bio (BLTE) director Lu Ita reports 110,000-share option stake - Stock Titan
Belite Bio (BLTE) director details stock option grants and vesting - Stock Titan
Belite Bio (BLTE) CEO Lin Yu-Hsin details option and share holdings - Stock Titan
Belite Bio (BLTE) director reports initial ADS and ordinary share stakes - Stock Titan
(BLTE) Risk Channels and Responsive Allocation - Stock Traders Daily
Belite Bio Stock Stumbles as Traders Flee Rally - TipRanks
Short Interest in Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Expands By 16.2% - MarketBeat
Belite Bio Details Phase 3 DRAGON Win as Tinlarebant Cuts Stargardt Lesion Growth 36% at Conference - Defense World
Mizuho reiterates Belite Bio stock rating on NDA timeline update By Investing.com - Investing.com Nigeria
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
H.C. Wainwright raises Belite Bio stock price target on NDA timeline - Investing.com Nigeria
Belite Bio Eyes 2027 Launch After Pivotal Win - TipRanks
Belite Bio (BLTE) to Release Earnings on Monday - MarketBeat
Belite Bio (NASDAQ:BLTE) Rating Increased to Hold at Wall Street Zen - MarketBeat
What is HC Wainwright’s Forecast for Belite Bio Q1 Earnings? - Defense World
(BLTE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Q1 Earnings Forecast for Belite Bio Issued By HC Wainwright - MarketBeat
Mizuho reiterates Belite Bio stock rating on NDA timeline update - Investing.com Australia
Belite Bio Q4 Earnings Call Highlights - Defense World
Belite Bio (NASDAQ:BLTE) Given New $266.00 Price Target at Cantor Fitzgerald - Defense World
Morgan Stanley Issues Positive Forecast for Belite Bio (NASDAQ:BLTE) Stock Price - Defense World
Belite Bio (NASDAQ:BLTE) Price Target Raised to $200.00 at HC Wainwright - MarketBeat
Belite Bio (BLTE) Q4 2025 Earnings Call Transcript - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Price Target Raised to $201.00 - MarketBeat
Belite Bio stock price target raised to $217 by Benchmark on trial data - Investing.com Canada
Belite Bio (NASDAQ:BLTE) Price Target Raised to $266.00 at Cantor Fitzgerald - MarketBeat
Cantor Fitzgerald raises Belite Bio stock price target on pricing outlook By Investing.com - Investing.com South Africa
Cantor Fitzgerald raises Belite Bio stock price target on pricing outlook - Investing.com Nigeria
Earnings call transcript: Belite Bio beats Q4 2025 EPS expectations, stock dips slightly - Investing.com
Belite Bio (NASDAQ:BLTE) Shares Down 8.6%What's Next? - MarketBeat
Belite Bio to Participate in the Leerink Global Healthcare Conference - The Manila Times
Belite Bio Posts 2025 Results as Tinlarebant Nears NDA Filing After Phase 3 Win - TipRanks
Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - The Manila Times
Stargardt Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ocugen, Kubota Vision Inc, Nanoscope Therapeutics, RBP4 Pty Ltd, Stargazer Pharma, Belite Bio, Alkeus Pharma - Barchart.com
Exploring Belite Bio's Earnings Expectations - Sahm
Liquidity Mapping Around (BLTE) Price Events - Stock Traders Daily
Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter ... - Caledonian Record
China Universal Asset Management Co. Ltd. Acquires New Position in Belite Bio, Inc. Sponsored ADR $BLTE - Defense World
Belite Bio (NASDAQ:BLTE) Shares Gap UpStill a Buy? - MarketBeat
Belite Bio Inc Adr Stock (BLTE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):